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Background: The purpose of this study is to investigate the prognostic role of insulin-like growth factor receptor 1
(IGF1R) expression in surgically resected non-small-cell lung cancer (NSCLC).
Patient characteristics and methods: This retrospective study was conducted in 369 stage I–II–IIIA, surgically
resected, NSCLC patients. Patients exposed to anti-epidermal growth factor receptor (EGFR) agents were excluded.
IGF1R expression was evaluated by immunohistochemistry in tissue microarray sections.
Results: A positive IGF1R expression (score ‡ 100) was observed in 282 cases (76.4%) and was significantly
associated with squamous cell histology (P = 0.04) and with grade III differentiation (P = 0.02). No difference in survival
was observed between the positive and negative group when score 100 was used as cut-off for discriminating a positive
versus a negative IGF1R result (52 versus 48 months, P = 0.99) or when median value of IGF1R expression was used
(45 versus 55 months, P = 0.36). No difference in survival was observed between IGF1R-positive and -negative patients
in a subgroup of stage I–II adenocarcinoma (n = 137) with known EGFR mutation and copy number status.
Conclusions: IGF1R expression does not represent a prognostic factor in resected NSCLC patients. Patients with
squamous cell carcinoma overexpress IGF1R more frequently than patients with nonsquamous histology, justifying the
different sensitivity to anti-IGF1R agents observed in clinical trials.
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introduction
In 2008, non-small-cell lung cancer (NSCLC) remains the
leading cause of cancer-related deaths worldwide [1]. Prognosis
for patients diagnosed with advanced NSCLC continues to be
dismal and distant metastases develop in up to 70% of patients
with early-stage disease, despite complete tumor resection,
leading to a 5-year survival rate of 40% [2]. Recent
discoveries in the field of lung cancer biology led to the clinical
development of new drugs able to interfere with tumor cell
proliferation. Among such agents, the mAb bevacizumab and
drugs targeting the epidermal growth factor receptor (EGFR)
demonstrated to significantly improve survival of NSCLC
patients with advanced disease when used in combination with
chemotherapy [3, 4] or as single agent [5].
The insulin-like growth factor receptor 1 (IGF1R) is
a transmembrane heterotetrameric protein encoded by a gene
located on chromosome 15q26.3 implicated in promoting
oncogenic transformation, growth and survival of cancer cells
[6–9]. IGF1R activation triggers a cascade of reactions
involving two signal transduction pathways [10, 11]: one
activates Ras, Raf and mitogen-activated protein kinase and the
other involves phosphoinositol-3-kinase (PI3K). Agents
targeting IGF1R demonstrated promising activity against
metastatic NSCLC when used in combination with
chemotherapy, particularly in patients with squamous cell
histology [12]. Preclinical models showed that IGF1R
expression could be implicated in acquired resistance to
anti-EGFR strategies [13, 14]. Chakravarti et al. [13]
demonstrated that IGF1R can compensate for loss of EGFR
function in primary glioma cell lines. In breast and prostate
cancer cells, Jones et al. [14] showed that increased signaling via
the IGF1R pathway leads to acquired resistance to the EGFR
tyrosine kinase inhibitor gefitinib. In two previous studies, we
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evaluated whether IGF1R expression and gene copy number
affected response to gefitinib or cetuximab in NSCLC and
colorectal cancer, respectively [15, 16]. Although both studies
demonstrate no association of IGF1R gene copy number or
protein expression with response to anti-EGFR agents, patients
overexpressing IGF1R had significantly longer survival than
individuals lacking the protein. These findings raised the
question whether IGF1R expression represented a prognostic
rather than a favorable predictive factor for survival in NSCLC
and colorectal cancer patients exposed to anti-EGFR drugs. The
prognostic role of IGF1R has been previously investigated in
human malignancies including NSCLC, leading to conflicting
results [17–19]. In NSCLC, a previous study showed
a nonsignificant shorter survival for IGF1R-overexpressing
patients compared with individuals with low or absent IGF1R
expression [19], indicating that IGF1R expression represents
a negative prognostic factor.
The conflicting available data and the growing interest on anti-
IGF1R agents support the present study aimed to investigate the
prognostic significance of IGF1R expression in NSCLC.
patient characteristics and methods
cohort
The present study was conducted retrospectively in a cohort of early-stage
(I–IIIA) NSCLC patients who received radical resection of a primary
NSCLC at the Istituto Clinico Humanitas IRCCS, Rozzano, Italy, from 2000
to 2004. Selection criteria included availability of tumor tissue from
primary lung cancer, pathologically confirmed stage I, II or IIIA and
survival data. In order to avoid any confounding effect of postsurgery
chemotherapy, we restricted our observation to patients who received
surgery before adjuvant chemotherapy became a standard approach.
Moreover, patients exposed to anti-EGFR agents at relapse were
excluded. The study was approved by the local ethics committee and was
conducted in accordance with ethical principles stated in the most recent
version of the Declaration of Helsinki or the applicable guidelines on good
clinical practice, whichever represented the greater protection to the
individuals.
tissue microarray, antibody and immunohistochemistry
Paraffin-embedded tumor specimens were used to construct a tissue
microarray with 600-um diameter cores. Each patient was represented by
three tissue cores. An adhesive-coated tape system (Instrumedics,
Hackensack, NJ) was used for sectioning the tumor array blocks at 4 lm.
Sections were stained with antibodies against IGF1R (Novus Biologicals,
Littleton, CO) according to the manufacturers’ recommended protocols.
Immunohistochemical (IHC) staining was carried out at the Pathology
Department of the Bellaria Hospital and slides were interpreted
independently by three observers at the University of Colorado Cancer
Center (WAF, GF and RSW) who were blinded to all patient information.
Images were obtained by using the digitizing pathology system APERIO
(Aperio Technology Inc., Vista, CA).
A semiquantitative approach was used to generate a score for each tissue
core. The percentage of positive cells per core (from 0% to 100%) was
multiplied by the dominant intensity pattern of staining, considering 1 as
negative or trace, 2 as weak, 3 as moderate and 4 as strong. Therefore, the
overall score ranged from0 to 400.When heterogeneous results were detected
among the three tested cores, themean value was used to represent the patient
in the statistical analyses. Based on our previously published classification
[15, 16], an IGF1R protein expression below 100 qualified the patient as
negative (IGF1R2), while a score ‡100 qualified the sample as positive
(IGF1R+). Analysis was also carried out using median value as the cut-off.
statistical analyses
The objective of the study was to assess whether IGF1R expression affected
survival of surgically resected NSCLC patients. Overall survival (OS),
calculated from the time of diagnosis to patient death or last contact, was
evaluated using Kaplan–Meier method [20] and hazard ratio was calculated
by using the Cox proportional hazards regression model. Associations with
clinical characteristics were compared by v2 test. OS for the groups with
negative and positive biomarker was compared using the log-rank test.
Statistical significance was set at <0.05 for each analysis. All statistical
analyses were carried out using R package.
results
patient characteristics
A total of 369 surgically resected NSCLC patients were included
in the present analysis. As shown in Table 1, the majority of
patients were male (85.6%), former (52.0%) or current (36.0%)
smokers, with moderately or poorly differentiated tumors
(grade II and III). The median age was 66.7 years. All patients
received radical surgery, with evidence of pathological stage I in
43.1%, stage II in 26.0% and stage III in 30.9%. Patients with
stage III disease and pathological evidence of N2 disease
(N = 85) received postoperative mediastinal radiotherapy.
With a median follow-up of 60 months, a total of 185 patients
died and median survival was 50 months. As expected, median
survival was longer in stage I–II than in stage III (not reached
Table 1. Patient characteristics
Characteristic Total %
Total 369 100.0
Median age (years; range) 66.7 (37.4–85.1)
Gender
Male 316 85.6
Female 53 14.4
Smoking history
Never 30 8.2
Former 192 52.0
Current 133 36.0
Unknown 14 3.8
Histology
Adenocarcinoma + bronchioloalveolar 185 50.1
Squamous cell carcinoma 132 35.8
Othera 52 14.1
Pathological stage
I 159 43.1
II 96 26.0
III 114 30.9
Grade
I 27 7.3
II 205 55.5
III 125 33.9
Not defined 12 3.3
aOther histology included seven patients with large-cell carcinoma, 21 cases
with neuroendocrine differentiation, eight undifferentiated NSCLC and 16
not specified NSCLC.
NSCLC, non-small-cell lung cancer.
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versus 21 months, P < 0.001). No significant difference in
survival was observed according to gender, smoking history,
histology or grading.
IGF1R results
Median IGF1R expression score was 133.3. A positive
expression (score ‡ 100) was observed in 282 cases (76.4%),
while 87 patients (23.6%) had very low or no IGF1R
expression. Interestingly, a positive IGF1R score was
significantly associated with squamous cell histology
(P = 0.04) and with grade III differentiation (P = 0.02), with
no significant association with any other clinical
characteristic, including gender, histology, smoking status
and stage, as presented in Table 2. As illustrated in Figure 1,
no difference in survival was observed between the positive
and negative group (52 versus 48 months, P = 0.99). Table 3
reports survival results in IGF1R-positive and -negative
patients according to clinical characteristics, and no difference
in survival was observed in any subgroup. In order to
investigate whether a different cut-off could better
discriminate populations with different survival outcome,
we analyzed patient survival using the median IGF1R
expression as cut-off value. As illustrated in Figure 2,
median survival was no different in patients with IGF1R
Table 2. IGF1R expression and association with clinical characteristics
Characteristic IGF1R+
(N/%)
IGF1R2
(N/%)
P value
All 282/76.4 87/23.6
Female 38/71.7 15/28.3 0.38
Male 244/77.2 72/22.8
Never smokers 21/70.0 9/30.0 0.44
Smokers (former + current) 248/76.3 77/23.7
Squamous cell carcinoma 109/82.6 23/17.4 0.04
Other histology 173/73.0 64/27.0
Grade I–II 168/72.4 64/27.6 0.02
Grade III 104/83.2 21/16.8
Stage I–II 198/77.7 57/22.3 0.41
Stage III 84/73.7 30/26.3
IGF1R, insulin-like growth factor receptor 1.
Table 3. Survival in IGF1R-positive and -negative patients according to
clinical characteristics
Characteristic IGF1R+
(N/months)
IGF1R2
(N/months)
P value
All 282/52 87/48 0.99
Female 38/42 15/NR 0.51
Male 244/55 72/46 0.75
Never smokers 21/42 9/NR 0.78
Smokers (former
+ current)
248/49 77/46 0.78
Adenocarcinoma
+ bronchioloalveolar
133/49 52/44 0.93
Squamous cell
carcinoma
109/NR 23/48 0.45
Other histology 40/21 12/30 0.21
Grade I–II 168/56 64/49 1.0
Grade III 104/38 21/27 0.70
Stage I–II 198/NR 57/NR 0.85
Stage III 84/21 30/24 0.53
IGF1R, insulin-like growth factor receptor 1; NR, not reached.
Figure 1. Survival in resected non-small-cell lung cancer with positive or
negative IGF1R expression. In the study population, the 282 patients
(76.4%) with positive IGF1R expression (score ‡ 100, IGF1R+) had
a median survival of 52 months versus 48 months in the 87 patients
(23.6%) with low or no IGF1R expression (<100, IGF1R2). The difference
was not statistically significant (P value 0.98). IGF1R, insulin-like growth
factor receptor 1.
Figure 2. Survival of resected non-small-cell lung cancer with IGF1R
expression above (IGF1R+) or below (IGF1R2) median value. Assuming
as positive for IGF1R individuals with protein expression above the
median score (>133.3) and as negative for patients with protein levels
below the median score (£133.3), median survival was 45 months in
patients IGF1R+ and 55 months in IGF1R2. The difference was not
statistically significant (P value 0.36). IGF1R, insulin-like growth factor
receptor 1.
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expression below or above the median value (55 versus 45
months, P = 0.36).
IGF1R and EGFR
Because of the cross talk between IGF1R and EGFR and the
potential implications of IGF1R in resistance to anti-EGFR
agents [13, 14], we further investigated the role of IGF1R
expression in a subgroup of 137 stage I–II adenocarcinoma
patients with known EGFR status. All 137 patients were
investigated for the presence of EGFR gene mutations and 111
were evaluated for EGFR copy number by FISH. EGFR
resulted mutated (exon 19 or 21) in 12 cases (8.8%), and 47
patients (42.3%) resulted EGFR FISH positive defined
according to criteria previously reported [21]. IGF1R
expression was not associated with EGFR gene copy number
(P = 0.65) or with the presence of EGFR mutations
(P = 0.23). No difference in survival was observed in EGFR
FISH-positive or -negative patients according to IGF1R
expression, as well as in patients with or without EGFR
mutations, as illustrated in Figure 3A–D.
discussion
In the present study, the largest to our knowledge exploring the
prognostic role of the IGF1R protein, we demonstrated that the
survival outcome of early-stage, resected NSCLC patients is not
different in individuals with low or high IGF1R expression.
There is an increasing interest on IGF1R in NSCLC. Several
new drugs, including mAbs and tyrosine kinase inhibitors, are
currently under evaluation in patients with advanced NSCLC.
A recent phase II study randomly assigned 150 chemonaive
NSCLC patients to the standard combination of carboplatin
plus paclitaxel versus the same regimen plus CP-751,871, an
anti-IGF1R mAb [12]. The study showed a significant
improvement in response rate favoring the experimental arm,
with an impressive 78% response rate in patients with
squamous histology. The higher expression of the IGF1R
protein in patients with squamous cell carcinoma compared
with nonsquamous histology observed in the present report, as
well as in a previous study [22], provides the biological
background for the highest sensitivity to anti-IGF1R agents
observed in clinical trials in this patient population.
Figure 3. IGF1R expression and survival according to EGFR gene copy number and mutation. The panel shows patient survival in IGF1R+ (score ‡ 100)
and IGF1R2 (score < 100) according to presence of EGFR mutations and according to EGFR gene copy number. (A) In EGFR FISH2 patients (n = 64,
57.7%), the difference in survival between IGF1R+ (n = 48) and IGF1R2 (n = 16) was not significant (45 months versus not reached, P value 0.14). (B)
Among EGFR FISH+ patients (n = 47, 42.3%), median survival was not reached in IGF1R+ (n = 37) and was 41 months in IGF1R2 (n = 10). The
difference was not statistically significant (P value 0.10). (C) Among EGFR wild-type patients (n = 125), 93 were IGF1R+ and 32 IGF1R2. Median survival
was 71 months in IGF1R+ versus not reached in IGF1R2. The difference was not statistically significant (P value 0.81). (D) In the small subgroup of patients
with EGFR mutations (n = 12), median survival was 42 months in the seven patients IGF1R+ and 32 months in the five IGF1R2 patients. The difference
was not statistically significant (P value 0.39). IGF1R, insulin-like growth factor receptor 1; EGFR, epidermal growth factor receptor.
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The prognostic role of IGF1R expression in NSCLC has been
previously investigated in three small retrospective studies [19,
22, 23], all using IHC for biomarker assessment. In the study
conducted by Merrick et al., a total of 184 stage I–IV NSCLC
were analyzed for IGF1R expression. Although patients with
high IGF1R expression had shorter survival than individuals
with low IGF1R levels, particularly in stage I, in the whole
population the difference was not statistically significant [19].
The study conducted by Ludovini et al. [22] in 125 NSCLC
patients reported no difference in survival between patients
with negative or positive immunostaining. Finally, Korean
investigators reported that IGF1R expression did not affect
survival of 71 NSCLC patients with surgically resected stage I
disease [23]. The main limitations of the above mentioned
studies were the relatively small number of analyzed patients
and the lack of data on anti-EGFR therapies eventually given
to relapsing patients. When assessing IGF1R, the potential
confounding effect of anti-EGFR strategies on patient survival
could be a relevant issue since recent data indicated that
individuals with high IGF1R expression benefited more from
gefitinib [15, 24] or cetuximab [16] therapy. In our previous
study, conducted in a small cohort of metastatic NSCLC
patients treated with gefitinib, patients with high levels of
IGF1R expression survived longer than individuals lacking
protein expression [15]. More recently, Fidler et al. [24] showed
improved efficacy with increased IGF1R expression in NSCLC
patients treated with gefitinib. Why patients with high IGF1R
expression should survive longer when treated with anti-EGFR
agents is unclear and needs further investigation. In the present
report, conducted in a large cohort of patients without the
potential confounding effect of anti-EGFR strategies, we
demonstrated that IGF1R expression levels have no impact on
patient survival. No association with patient survival was
observed irrespective of the adopted scoring system, with no
linear association between IGF1R expression and duration of
survival (data not shown). All together, these data, collected at
the protein level using IHC staining, do not support
a prognostic role for IGF1R.
In the present study, we did not investigate Kras status and
the potential correlation with IGF1R expression. Although Kras
mutation could be responsible for resistance to anti-IGF1R
strategies, at present no data support this hypothesis.
In conclusion, this study demonstrated that IGF1R expression
does not represent a prognostic factor in resected NSCLC
patients. Patients with squamous cell carcinoma express IGF1R
more frequently than patients with nonsquamous histology,
justifying the different sensitivity to anti-IGF1R agents observed
in clinical trials. Further studies should investigate the possible
role of IGF1R as predictive factor for survival in individuals
receiving anti-EGFR treatments.
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